SARS-CoV-2 Spike (1171-1185) 0.5mg


  • Description

  • Application Data


GINASVVNIQKEIDR is an epitope from the SARS-CoV-2 spike protein (1171-1185). It is an epitope suitable for anti-viral targeting.

See full description

Application Data

Catalogue number crb1001823h
Molecular Weight 1654.9
Sequence (one letter code)


Sequence (three letter code)


Purity >95%
Storage -20°C

Jiang et al., (2022). SARS-CoV-2 Omicron Variant is Expected to Retain Most of the Spike Protein Specific Dominant T-Cell Epitopes Presented by COVID-19 Vaccines — Worldwide. China CDC Weekly, 4(18): 381. DOI: 10.46234/ccdcw2022.065.

Manufactured in: United Kingdom
Material Safety Data Sheet (MSDS)

The SARS-CoV-2 spike protein is present on the outside of the virus particles and can bind to angiotensin-converting enzyme II (ACE2) present on the host cells. The C-terminal receptor binding domain (RBD) of the spike protein binds to the N-terminal peptidase M2 domain of ACE2. This receptor binding results in the internalisation of the virus-receptor complex and is, therefore the mechanism of entry of SARS-CoV-2 into host cells.

The spike protein residues GINASVVNIQKEIDR (1171-1185) from C have been identified as a T-cell epitope with a predicted HLA restriction. Immune targeting of confirmed epitopes may potentially offer protection against SARS-CoV-2 and help the development of vaccines for long-lasting immunity.

We have a large collection of SARS-CoV-2 for you to choose from to complement your research. Explore our antiviral peptides, COVID-19 peptides, and epitope families here for the full list.

SARS-CoV-2 Spike (1171-1185) 0.5mg

Bulk Quote

You may also like…

  • SARS-CoV-2 Spike (1196-1205)


    View products
  • SARS-CoV-2 Spike (991-1000)


    View products
  • SARS-CoV-2 Spike (975-989)


    View products
  • SARS-CoV-2 Spike (1192-1200)


    View products